Teva launches generic niacin extended-release tablets

Drug maker gets 180 days' generic exclusivity

JERUSALEM — Teva Pharmaceutical Industries has launched a generic drug for treating cardiovascular disease, the company said.

Teva announced the launch of niacin extended-release tablets in the 500-mg, 750-mg and 1,000-mg strengths. As the first company to file for approval of the drug, Teva will have 180 days in which to market the generic version exclusively.

The drug is a generic version of AbbVie's Niaspan, used to treat elevated low-density lipoprotein or "bad" cholesterol, triglycerides and other lipids in the blood. Niaspan had sales of about $1.12 billion during the 12 months ended in June, according to IMS Health.

Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.

Login or Register to post a comment.